Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct-Dec;24(4):1073274817729901.
doi: 10.1177/1073274817729901.

Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review

Chandrashekar Bohra  1   2   3 , Lubomir Sokol  1   2   3 , Samir Dalia  1   2   3
Affiliations
Review

Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review

Chandrashekar Bohra et al. Cancer Control. 2017 Oct-Dec.

Abstract

Progressive multifocal leukoencephalopathy (PML) is a viral infection predominantly seen in patients with HIV infection. However, with the increased use of monoclonal antibodies (MAB) for various lymphoproliferative disorders, we are now seeing this infection in non-HIV patients on drugs such as natalizumab, rituximab, and so on. The aim of this article is to review the relationship between the occurrence of PML and MAB used in the treatment of hematological malignancies and autoimmune diseases. Review of articles from PubMed-indexed journals which study PML in relation to the use of MAB. Relevant literature demonstrated an increased risk of reactivation of latent John Cunningham polyomavirus (JCV) resulting in development of PML in patients on long-term therapy with MAB. The highest incidence of 1 PML case per 1000 treated patients and 1 case per 32 000 was observed in patients treated with natalizumab and rituximab, respectively. Serological and polymerase chain reaction tests for the detection of JCV can be helpful in risk stratification of patients for the development of PML before and during therapy with MAB. Treatment with MAB can result in development of PML. Clinicians should include PML in differential diagnosis in patients treated with these agents if they manifest central nervous system symptoms.

Keywords: JCV; monoclonal antibodies; progressive multifocal leukoencephalopathy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Astrom KE, Mancall EL, Richardson EP., Jr Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin’s disease. Brain. 1958;81(1):93–111. - PubMed
    1. ZuRhein G, Chou S. Particles resembling papovavirons in human cerebral demyelinating disease. Science. 1965;148(3676):1477–1479. - PubMed
    1. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2(2):299–313. - PubMed
    1. Bernick C, Gregorios JB. Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome. Arch Neurol. 1984;41(7):780–782. - PubMed
    1. Miller JR, Barrett RE, Britton CB, et al. Progressive multifocal leukoencephalopathy in a male heterosexual with T cell immunodeficiency. N Engl J Med. 1982;307(23):1436–1438. - PubMed

MeSH terms

Substances

LinkOut - more resources